| PLCB3 — Phospholipase C Beta 3 | |
|---|---|
| Gene Symbol | PLCB3 |
| Full Name | Phospholipase C Beta 3 |
| Chromosome | 11q13.1 |
| NCBI Gene ID | [5293](https://www.ncbi.nlm.nih.gov/gene/5293) |
| OMIM | [607330](https://www.omim.org/entry/607330) |
| Ensembl ID | ENSG00000149792 |
| UniProt ID | [Q9Y886](https://www.uniprot.org/uniprot/Q9Y886) |
| Protein Name | Phospholipase C beta 3 |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), Type 2 Diabetes |
PLCB3 is a human gene whose product PLCB3 (Phospholipase C Beta 3) is a widely expressed phosphoinositide-specific phospholipase C isoform. It generates IP3 and DAG from PIP2, mediating G-protein coupled receptor signaling. PLCB3 has tissue-specific roles in neuronal signaling, cardiac function, and pancreatic beta-cell insulin secretion[1]. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
PLCB3 (Phospholipase C Beta 3) is a widely expressed phosphoinositide-specific phospholipase C isoform. It generates IP3 and DAG from PIP2, mediating G-protein coupled receptor signaling. PLCB3 has tissue-specific roles in neuronal signaling, cardiac function, and pancreatic beta-cell insulin secretion[1:1].
PLCB3 participates in calcium signaling pathways important for neuronal viability[2]:
| Target | Approach | Status |
|---|---|---|
| PLC modulators | Small molecule inhibitors | Research |
| Calcium stabilizers | Calcium channel modulators | Preclinical |
| Gene therapy | PLCB3 expression modulation | Research |
Lyons et al. The PLC family (2020). 2020. ↩︎ ↩︎
Kang et al. PLCB3 and calcium signaling in neurodegeneration (2021). 2021. ↩︎